NCT02586987View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 28, 2015

Primary Completion Date

July 25, 2018

Study Completion Date

September 20, 2019

Conditions
Lung CancerMelanomaHead and Neck CarcinomaGastroesophageal CancerBreast CancerPancreatic AdenocarcinomaColorectal CancerBiliary Tract Cancer
Interventions
DRUG

Selumetinib

Selumetinib oral

DRUG

MEDI4736

MEDI4736 IV

DRUG

Tremelimumab

Tremelimumab, IV

Trial Locations (6)

15232

Research Site, Pittsburgh

28204

Research Site, Charlotte

60637

Research Site, Chicago

02215

Research Site, Boston

89169-3321

Research Site, Las Vegas

08901

Research Site, New Brunswick

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY